250 East Grand Avenue
South San Francisco
6 articles about Septerna, Inc.
Septerna today announced that it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired an undisclosed discovery-stage GPCR program.
Septerna Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies
Septerna announced the addition of David Martin, Ph.D., as Senior Vice President of Development Sciences, and Samira Shaikhly as Chief People Officer to its leadership team.
Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines
Septerna, a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors, announced the closing of a $150 million Series B financing.
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
Septerna today announced the establishment of its cross-functional scientific and drug discovery advisory board with seasoned industry drug hunters and leading academic GPCR biology and pharmacology scientists.
After reaching a record high in 2021, venture capital dollars have tailed off in the biopharma industry in 2022. That said, a few biopharma hotbeds have still seen sizeable launch rounds.